5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020

Summary

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Respiratory which include indications Psychiatric Disorders, Alzheimer's Disease, Cognitive Disorders, Schizophrenia, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder (Manic Depression), Dementia, Depression, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Major Depressive Disorder, Neurology, Obesity, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension and Schizoaffective Disorder.

The latest report 5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
• The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
• The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope